Created in 2006 (Denmark), LEAD programme Liraglutide Effect and Action in Diabetes own 307 sister brands and 2214 competing brands. LEAD programme Liraglutide Effect and Action in Diabetes is owned by NOVO-NORDISK A/S, listed on the stock exchange of Francfort LEAD programme Liraglutide Effect and Action in Diabetes belongs to the Biotechnology business sector.

LEAD programme Liraglutide Effect and Action in Diabetes is a brand of NOVO-NORDISK A/S (NOVA) Share price

International deposit : 2006 Business sector Biotechnology

Share price and profitability of the share NOVO-NORDISK A/S (LEAD programme Liraglutide Effect and Action in Diabetes)

Buy NOVO-NORDISK A/S share with
(0% commission and fractional shares)
Your capital is subject to risk. Other fees apply. For more information, visit etoro.com/trading/fees.

Investment simulator :

Amount invested EUR 118.50

Portfolio valuation
NOVO-NORDISK A/S (LEAD programme Liraglutide Effect and Action in Diabetes) over 5 years* EUR 641.20

Stock market history NOVO-NORDISK A/S (LEAD programme Liraglutide Effect and Action in Diabetes)

*non inclusive of dividends, non inclusive of market orders
past performances do not prejudice future performances

Other brands
NOVO-NORDISK A/S

INVERSAGO
INVERSAGO
Corvidia
Corvidia
Calibrium
Calibrium
MB2
MB2
ZIYLO
ZIYLO
Novo-Nordisk
Novo-Nordisk
See more brands of NOVO-NORDISK A/S

Rival brands
LEAD programme Liraglutide Effect and Action in Diabetes

NOTABLE LABS
NOTABLE LABS
Roivant
Roivant
Valerio Therapeutics
Valerio Therapeutics
Terns Pharma
Terns Pharma
Vaxcyte
Vaxcyte
ZEVRA THERAPEUTICS
ZEVRA THERAPEUTICS
OTHER RIVAL BRANDS

Top Popularity Web

See the full ranking
Desirable brands that generate Pricing Power and therefore stock market performance
Desirable brands that generate Pricing Power and therefore stock market performance

Only companies with a strong brand or unique know-how benefit from this ability to set their prices without impacting demand and thus preserve their margins.

Read more
MORE NEWS